Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases

LAUR Repository

Show simple item record

dc.contributor.author Ribero, David
dc.contributor.author Wang, Huamin
dc.contributor.author Donadon, Matteo
dc.contributor.author Zorzi, Daria
dc.contributor.author Thomas, Melanie
dc.contributor.author Eng, Cathy
dc.contributor.author Chang, David
dc.contributor.author Curley, Steven
dc.contributor.author Abdalla, Eddie
dc.contributor.author Ellis, Lee
dc.contributor.author Vauthey, Nicolas
dc.date.accessioned 2015-11-16T10:54:58Z
dc.date.available 2015-11-16T10:54:58Z
dc.date.copyright 2007
dc.date.issued 2015-11-16
dc.identifier.issn 0008-543X en_US
dc.identifier.uri http://hdl.handle.net/10725/2578
dc.description.abstract BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX chemotherapy with (n 5 62) or without (n 5 43) bevacizumab were analyzed. The response to chemotherapy was evaluated by pathologic analysis of tumor viability (percentage of viable tumor in relation to tumor surface area). The incidence and grade of hepatic sinusoidal dilation were also investigated. RESULTS. Bevacizumab-containing regimens significantly reduced the degree of tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P 5 .02). After stratification according to the magnitude of tumor viability, a higher proportion of patients treated with bevacizumab than without had <25% residual viable tumor cells (45% vs 23%; P 5 .02). However, the addition of bevacizumab to 5FU/OX did not appear to increase the incidence of complete pathologic response (11.3% vs 11.6%; P 5 .59). The incidence and severity of sinusoidal dilation was lower in patients treated with bevacizumab than in those treated with 5FU/OX only (any grade: 27.4% vs 53.5%; moderate or severe: 8.1% vs 27.9%; both P <.01). CONCLUSIONS. In patients treated with 5FU/OX chemotherapy, bevacizumab improves the pathologic response, as demonstrated by a reduction of the degree of tumor viability, and reduces the incidence and severity of hepatic injury. This retrospective study provides additional evidence supporting the use of bevacizumab in combination with 5FU/OX for CLM. Cancer 2007;110:2761–7. 2007 American Cancer Society en_US
dc.language.iso en en_US
dc.title Bevacizumab Improves Pathologic Response and Protects Against Hepatic Injury in Patients Treated With Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Cancer en_US
dc.journal.volume 110 en_US
dc.journal.issue 12 en_US
dc.article.pages 2761-2767 en_US
dc.keywords Oxaliplatin en_US
dc.keywords Bevacizumab en_US
dc.keywords Tumor response en_US
dc.keywords Colorectal liver metastases en_US
dc.keywords Sinusoidal dilatation en_US
dc.keywords Hepatotoxicity en_US
dc.identifier.doi http://dx.doi.org/10.1002/cncr.23099 en_US
dc.identifier.ctation Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M. B., Eng, C., ... & Vauthey, J. N. (2007). Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases. Cancer, 110(12), 2761-2767. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://onlinelibrary.wiley.com/doi/10.1002/cncr.23099/full

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account